Literature DB >> 1341270

Factors affecting outcome in locally advanced breast cancer.

E R Sanchez-Forgach1, E P Mamounas, J Warneke, D Driscoll, L E Blumenson, T N Tsangaris.   

Abstract

Patients presenting with locally advanced breast cancer (LABC) constitute a diverse group for which a variety of treatment modalities have been instituted. To assess which factors have a direct impact on outcome, we reviewed the medical records of 104 patients diagnosed with stage IIIA, stage IIIB and T3N0M0 breast carcinoma. When considered individually (univariate analysis), clinical stage, pathological stage, oestrogen receptor status and type of therapy were significant predictors for disease-free survival (DFS) and overall survival (OS). However, in a multivariate analysis, only clinical stage was a significant predictor for both DFS and OS, while ER status was a significant predictor for OS. There was a high degree of correlation between clinical and pathological staging. Nearly two-thirds of the patients developed a recurrence by 5 years. Loco-regional recurrence was the site of first recurrence in one-third of the patients by 5 years. The prognosis for patients presenting with LABC is poor, and they should be treated aggressively with loco-regional and systemic multimodality therapy. Although groups of patients with improved outcome could be identified by clinical or pathological staging, no group demonstrated an outcome good enough to be spared from multimodality therapy.

Entities:  

Mesh:

Year:  1992        PMID: 1341270     DOI: 10.1016/0960-7404(92)90035-j

Source DB:  PubMed          Journal:  Surg Oncol        ISSN: 0960-7404            Impact factor:   3.279


  2 in total

Review 1.  Locally advanced breast cancer in developing countries: the place of surgery.

Authors:  Justus P Apffelstaedt
Journal:  World J Surg       Date:  2003-06-06       Impact factor: 3.352

2.  Prediction of outcome in locally advanced breast cancer by post-chemotherapy nodal status and baseline serum tumour markers.

Authors:  B Brenner; N Siris; E Rakowsky; E Fenig; A Sulkes; H Lurie
Journal:  Br J Cancer       Date:  2002-12-02       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.